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Abstract 
Background: Detection of low-abundance biomarkers using mass spectrometry (MS) is often hampered by non- 
target molecules in biological fluids. In addition, current procedures for sample preparation increase sample con-
sumption and limit analysis throughput. Here, a simple strategy is proposed to construct an antibody-modified target 
plate for high-sensitivity MS detection of target markers such as insulin, in biological fluids.
Methods: The target plate was first modified with gold nanoparticle, and then functionalized with corresponding 
antibody through chemical conjugation. Clinical specimens were incubated onto these antibody-functionalized tar-
get plates, and then subjected to matrix assisted laser desorption ionization mass spectrometry analysis.
Results: Insulin in samples was enriched specifically on this functional plate. The detection just required low-volume 
samples (lower than 5 µL) and simplified handling process (within 40 min). This method exhibited high sensitivity 
(limit of detection in standard samples, 0.8 nM) and good linear correlation of MS intensity with insulin concentration 
(R2 = 0.994). More importantly, insulin present in real biological fluids such as human serum and cell lysate could be 
detected directly by using this functional target plate without additional sample preparations.
Conclusions: Our method is easy to manipulate, cost-effective, and with a potential to be applied in the field of clini-
cal biomarker detection.
Keywords: Insulin, MALDI MS, Antibody-enrichment, Chemical conjugation
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Background
The level of insulin in the blood indicates explicitly the 
function of endocrine beta cells, and thus the metabo-
lism situation of carbohydrates and fat. Thus, insulin is 
recognized as a marker protein for diagnosis of various 
types of diabetes and related diseases [1–6]. The detec-
tion of insulin in diabetes samples has been used in early-
diagnosis, monitoring disease progression, prognosis and 
pathology research [2]. The progression of technique for 
insulin analysis will undoubtedly improve the early diag-
nosis for relative disease and facilitate the follow-up ther-
apy [3, 4].
Currently, insulin analysis is based on a number of 
methods, including chemiluminescence immunoassays 
[7], radio immunoassays [8], immune affinity chroma-
tography-LC/MS/MS methods [9], surface plasma reso-
nance immunosensors [10], capillary electrophoretic 
immunoassay [11], and immune enzymometric assays 
[12]. However, most of these methods are time- and 
labor-consuming, of low analysis throughput, and use 
hazardous reagents such as the radioactive labels.
Matrix assisted laser desorption ionization mass 
spectrometry (MALDI MS) is a powerful tool for the 
detection and analysis of biomarkers [13]. Owing to 
the remarkable features such as high-throughput, high 
sensitivity, label-free analysis and ease to manipulate, 
MALDI MS-based analysis has gained considerable 
interest and is now widely utilized in different fields of 
biomolecule analysis (including discovery, identification 
Open Access
Clinical Proteomics
*Correspondence:  yanli001@gmail.com 
1 Laboratory of Interdisciplinary Research, Institute of Biophysics, Chinese 
Academy of Sciences, Beijing 100101, China
Full list of author information is available at the end of the article
Page 2 of 9Liang et al. Clin Proteom  (2017) 14:5 
and monitoring), and even as a diagnostic platform 
[14–17]. Nevertheless, directly detecting low-level bio-
molecules such as insulin is hampered by the complex 
composition of real biological fluids. The concentrations 
of target peptide or protein in blood generally range 
from nM to μM [18], which were much lower than many 
other non-target molecules and thus very hard to detect 
or quantify. In addition, the performance of MS is usu-
ally hampered by the high content of salts in biological 
fluids, known as the effect of ionization suppression [19]. 
Therefore, several immune-MALDI MS methods have 
been developed to pre-concentrate target analytes and 
increase analyzing efficiency. These methods generally 
applied immune-affinity column [20] or antibody-con-
jugated magnetic beads [21, 22] to capture target bio-
molecules, followed by MALDI MS analysis. However, 
these strategies required additional steps of centrifuga-
tion, sample transferring, or column-fractions, which 
increased sample consumption and limited the analysis 
throughput [13].
One solution is to specifically enrich target molecules 
on the MS target plate, to avoid additional handling 
processes such as column purification or sample trans-
fer. A small number of studies have reported the use of 
this strategy to detect insulin [23–25]. In these reported 
methods, the antibody of target analyte was immobilized 
on 2-dimension planar substrate by using complicated 
chemical reagents [23, 24] or non-specific adsorption 
[25]. However, the surface area of 2-dimension planar 
substrate was restricted, limiting the number of immobi-
lized antibodies and the approach of target analytes [23–
25]. Meanwhile, the complex organic chemicals such as 
dextran [24] may also introduce more non-target signals 
to MS analysis. Thus, the sensitivities of these strategies 
were generally in micromole range, hindering a more 
wide-spread application for the analysis of real biologi-
cal fluids [23, 25]. Therefore, new design of target plate 
substrate is still needed to direct analyze real biological 
fluids using MADLI MS with minimum sample prepara-
tion.
Here, to achieve facilitated and sensitive insulin detec-
tion, we designed a simple strategy to immobilize insu-
lin antibody directly onto a gold-nanostructured MALDI 
plate by means of chemical conjugation. The 3-dimen-
sion non-planar nano-surface increased surface area, 
and improved the efficiency of antibody binding, thus 
enhanced the sensitivity of analysis. Meanwhile, the 
simple small-molecular chemicals used in this platform 
avoided introducing interference signals in the MALDI 
MS. Compared with most previous immune-MALDI 
MS methods [20–22], this platform could simultaneously 
enrich and detect target insulin in biological fluids with-
out any off-plate purification by affinity-beads/column, 





droxybenzoic acid (DHB), Trifluoroacetic acid (TFA), 
bovine serum albumin (BSA), human serum albumin 
(HSA), transferring, immunoglobulin G (IgG), Acetoni-
trile (ACN), and 1-ethyl-3-(3-dimethylaminopropyl)car-
bodiimide (EDC) hydrochloride were purchased from 
Sigma (St. Louis, Mo, USA). 11-mercaptoundecanoic 
acid (MUA) was obtained from Aldrich (Milwaukee, WI, 
USA). N-Hydroxysuccinimide (NHS) was purchased 
from Acros (New Jersey, USA). HAuCl4 was purchased 
from J&K Scientific Ltd. (Beijing, China). NaOH, NaCl, 
HCl, HNO3, absolute ethanol, methanol, ethanolamine 
(EOA) were of analytical reagent grade from Beijing 
Chemical Works (Beijing, China). Antibody of human 
insulin was purchased from the Cell Signaling Technol-
ogy, Inc. ITO slides (10 Ω/sq) were purchased from Kaivo 
Electronic Components Co., Ltd. (Zhuhai, China). All 
reagents and solvents were used as received. Triply dis-
tilled water was used for the preparation of all solutions 
and rinsing.
Preparation of GNP
The gold nanoparticles (GNP) were prepared according 
to the previous literature [26]. All glassware used was 
cleaned in aqua regia solution (HCl:HNO3  =  3:1) and 
then thoroughly rinsed by distilled H2O. Briefly, 100 mL 
of 0.01% HAuCl4 was heated to boiling in a round-bot-
tom flask equipped with a condenser. Then 1.3 mL aque-
ous solution of sodium-citrate (1%) was added under 
vigorous stirring. In about 25 s, the solution turned blue; 
in approximately 1 min, the blue color change to red-vio-
let gradually. After that the solution was kept boiling for 
an additional 10 min, and then cooled at room tempera-
ture. The prepared nanoparticle was stored at 4 °C.
Surface modification of ITO slide
Silylation of ITO slide
The ITO glasses were cut into 25 × 37.5 mm slides and 
cleaned by sequential sonication in acetone for 20  min, 
in isopropanol for 20 min, in soap water for 15 min, and 
twice in distilled water for 10 min. The cleaned ITO slides 
were immersed in 5 M NaOH for 8 h at room tempera-
ture and then flushed thoroughly with distilled water and 
dried under N2 stream. Afterwards they were immedi-
ately treated in a freshly prepared APTMS solution (3% 
in methanol) for 2  h. The resulting APTMS-ITO slides 
were sonically cleaned in methanol for three times and 
dried under N2 stream.
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Deposition of GNP on APTMS‑ITO
The APTMS-ITO slides were immersed in GNP solu-
tion for at least 8 h at 4 °C prior to flushing with distilled 
water and dried under N2 stream.
Derivatization of carboxyl group on GNP‑ITO slide
The GNP deposited ITO (GNP-ITO) slides were 
immersed in a solution of MUA in ethanol (10 mM) for 
8 h, rinsed with ethanol, and then dried under N2 stream.
Immobilization of protein on MUA‑GNP‑ITO
To covalently attach protein on these two kinds of sub-
strate, an aqueous solution of EDC (75  mM) and NHS 
(15 mM) was first applied to treat the slides for 25 min 
at room temperature. Then the protein solutions (anti-
insulin or BSA in pH 7.4 phosphate buffer) were spotted 
directly on the proper locations of the slides using pipet-
tor. After all samples were spotted, the slides were laid in 
a sealed humid bottle at room temperature for at least 
2 h to complete coupling reaction. Then an aqueous solu-
tion of EOA (1 M, adjusted with 5 M HCl to pH 8.6) was 
applied to treat the slides for 1.5 h to block the unreacted 
carboxyl groups. Finally, the anti-insulin or BSA modified 
ITO slides were flushed thoroughly with water to clean 
the unbound proteins and dried under N2 stream.
Insulin immune‑reaction and MALDI‑TOF analysis
Human insulin (0–72 nM) was dissolved in pH 7.4 phos-
phate buffer (10 mM) or PBS buffer containing albumin 
(35 mg/mL), transferring (2 mg/mL) and IgG (6 mg/mL) 
to generate standard insulin solutions. Five microliter of 
insulin solution was dropped on the anti-insulin modified 
ITO slide and incubated on a shaking table at room tem-
perature for 30 min. Then the ITO plate was rinsed with 
Tween 20 solution (0.05% Tween 20 in water) and dis-
tilled water sequentially and dried under N2 stream. After 
that, 1 μL of DHB (15 mg/mL, 50% ACN, 0.1% TFA) was 
applied as the matrix for MALDI-TOF mass analysis. The 
solvent was dried naturally under room temperature and 
then the target plate was subjected to MALDI MS analy-
sis.
Mass spectrometry was acquired on SHIMADZU 
AXIMA Resonance MALDI-IT-TOF on reflective/posi-
tive ion mode. Laser power of 105  mV was selected as 
standard desorption energy in MS analysis.
Results and discussion
Strategy to anchor insulin antibody on MALDI MS target 
plate
An indium tin oxide coated glass slide (ITO slide) was 
selected as MALDI MS target plate due to its ease of 
chemical modification and excellent conductivity [26], 
the latter is important for the efficient MALDI MS 
analysis [25]. An easy approach to construct nano-sur-
face was designed, and used to immobilize the insulin 
antibody on the ITO slide by chemical conjugation.
The approach (Fig. 1) utilized gold-nanoparticle (GNP) 
to modify ITO surface. Three key steps were needed: 
derivatization of amino group on ITO slide with silani-
zation reagent APTMS [27]; deposition of GNP on the 
amino-terminated ITO slides [26]; derivatization of car-
boxyl group on the GNP-ITO and chemical coupling of 
antibody. The GNP with negative charged surface could 
be adsorbed stably on the amino-terminated ITO sur-
face through electrostatic interactions [26]. Compared 
with the 2-dimension planar surface of original ITO, the 
3-dimension nano-structure would greatly increase the 
surface area of target plate. Correspondingly, the anti-
bodies immobilized on plate surface increased, which 
was beneficial for capturing more insulin and increasing 
MS sensitivity [6]. A key factor to affect detection was the 
laser energy of MALDI MS, because weak laser power 
may not desorb the insulin immobilized by antibody. As 
shown in Fig.  2, when the laser energy was lower than 
65  mV, the signal was hardly detected. The MS signal 
intensity increased gradually as laser energy rose from 
65 to 105 mV, and kept stable after laser energy exceeded 
105  mV (Fig.  2). Because excessive laser energy may 
introduce additional noisy signal, we chose 105  mV as 
standard laser energy in our experiments to achieve the 
best signal intensity.
To prove the validity of this approach, either insu-
lin antibody or a control protein BSA were covalently 
anchored on the GNP-ITO slides. Subsequently, stand-
ard solutions of insulin were incubated on these two 
protein-modified plates, and then washed to remove any 
unbound or weakly bound species. As shown in Fig. 3a, 
on the BSA modified GNP-ITO (without antibody), no 
insulin signal could be detected (Fig. 3a). Meanwhile, by 
using the antibody-modified GNP-ITO as target plate, 
clear signal of insulin was identified (Fig. 3b), indicating 
that the insulin in samples was captured on the antibody-
functionalized plate and then detected by MALDI MS. 
Notably, there is no other noisy signals visible in the mass 
range, indicating that the designed target plate did not 
introduce interfering signals in this range.
To exclude the possibility of capturing non-target 
molecules on the antibody-modified GNP-ITO, a mix-
ture solution of insulin (34  nM) and non-target peptide 
(331  nM) was analyzed by using different target plates. 
As shown in Fig. 4, no recognizable peak can be observed 
on the BSA modified GNP-ITO (Fig. 4a). In addition, the 
conventional MALDI MS plate demonstrated abundance 
of both two peptides (Fig. 4b). As no separation method 
employed, the insulin signal was much lower than C-pep-
tide (Fig. 4b). In contrast, on the antibody-modified target 
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plate, the signal of C-peptide disappeared and only the 
clear peak of insulin was observed in spectrum (Fig. 4c). 
These evidences revealed that the antibody have been 
immobilized substantially on the target plate and specifi-
cally capture the target insulin in samples as we expected.
Sensitivity of the MALDI MS based on the anti‑insulin 
modified GNP‑ITO
Standard insulin samples at different concentrations were 
tested on the antibody-modified GNP-ITO. Five microlit-
ers of insulin solution were incubated on a circular area 
(diameter 4 mm) of the target plate for 30 min followed 
by washing with Tween 20 solution (0.05%) and water. 
After drying, DHB (15 mg/mL in 50% ACN, 0.1% TFA) 
was spotted on the circular area as MS matrix and the 
target plate was subjected to MALDI MS analysis. As 
illustrated in Fig. 5, strong signals of insulin at m/z 5809 
and 5791 were clearly detected. The insulin peaks could 
be resolved from the background (≥3 times of base-
line intensity) even when the insulin level was as low as 
0.8 nM. The limit of detection (LOD) at 0.8 nM obtained 
in standard solution is much lower than the previous 
reported similar works, in which the tested peptide lev-
els were usually at the range of micromole [25] or sev-
eral hundred nano-moles [24]. A good linear correlation 
Fig. 1 Schematic overview for the preparation of GNP-modified target plate and antibody-assisted enrichment and MS-detection of insulin
Fig. 2 MALDI MS intensity of standard insulin sample (8 nM) 
obtained at different laser energy power (45, 65, 85, 105, and 120 mV). 
Data represent MEAN ± SEM, n ≥ 3
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(R2  =  0.994) of MS intensity with insulin level was 
obtained in the range of 0.8–48 nM (Fig. 6). We also tried 
to test the performance of our method in complex bio-
fluids. Due to the difficulty to obtain insulin-free serum, 
we tried to mimic the serum by generating a buffer solu-
tion containing serum-abundant proteins such as albu-
min (35 mg/mL), transferring (2 mg/mL) and IgG (6 mg/
mL), which were added at the concentrations similar to 
real serum. As shown in Fig.  6, although the MS inten-
sity of insulin based on artificial matrix was lower than 
PBS buffer, a linear relation with R2 = 0.985 still could be 
observed in the range lower than 32  nM (Fig.  6). These 
results demonstrated the ability of our method to per-
form real bio-fluid analysis, and that the interference 
from sample matrix was limited.
A serial of parallel serum samples collected from 6 
patients accepting insulin therapy were also tested to 
investigate the reproducibility. Good repeatability was 
obtained in within and between day tests, as shown in 
Table 1. In short, sensitive detection of insulin was easily 
Fig. 3 MALDI MS spectra of standard insulin samples (8 nM). a MS Spectrum achieved on BSA modified GNP-ITO without anti-insulin antibody. b 
MS Spectrum achieved on anti-insulin antibody-modified GNP-ITO. 5 Replicates for each data were tested at the same conditions
Fig. 4 MALDI MS spectra of standard insulin (34 nM)/C-peptide (331 nM) mixture solution. a MS Spectrum achieved on BSA modified GNP-ITO 
without anti-insulin antibody. b MS Spectrum achieved on conventional target plate. c MS Spectrum achieved on anti-insulin antibody-modifed 
GNP-ITO. 5 Replicates for each data were tested at the same conditions
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achieved on this developed target plate, just requiring 
very low-volume sample and oversimplified handling 
process.
Fig. 5 MALDI MS spectra of standard insulin samples in different concentrations (0.8, 1.6, 4, 8, 16, 32, 48 nM) achieved on anti-insulin antibody-
modified GNP-ITO. 3 Replicates for each data were tested at the same conditions
Fig. 6 Correlation of MS intensity with the concentrations of insulin 
(0.8, 1.6, 4, 8, 16, 32, 48, 60, and 72 nM) spiked in PBS buffer (blue circle) 
or artificial serum-mimic (red square) containing albumin (35 mg/
mL), transferring (2 mg/mL) and IgG (6 mg/mL). Data represent 
MEAN ± SEM. n ≥ 3
Table 1 Repeatability of  MALDI MS results obtained 
on antibody-modified GNP-ITO in 6 patient serum samples 
(accepting insulin therapy)
Ten replicate measurements per sample per day were performed for 3 days to 







Patient 1 2.50 15.8 17.0
Patient 2 4.52 13.8 14.8
Patient 3 4.11 14.1 15.3
Patient 4 3.28 15.0 15.3
Patient 5 4.47 11.1 14.6
Patient 6 3.67 15.1 16.0
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Analysis of biological fluids
It is difficult to directly detect low-level targets in com-
plex samples using MALDI MS. The complicated compo-
sition and high level non-target molecules in biological 
fluids generally generated high background signals and 
interfered with the detection of target molecules. In 
addition, salts present in samples will greatly reduce 
the performance of MS analysis. Figure 7a indicated the 
MS spectrum by applying raw human serum (from the 
patients accepting insulin therapy) on the conventional 
MALDI plate, and no identified signals can be observed 
at m/z 5809 and 5791. Subsequently, the human sera 
were incubated and washed on the antibody-modified 
GNP-ITO and then subjected to MALDI MS analysis. 
As shown in Fig.  7b, the signals of insulin at m/z 5809 
and 5791 were discerned clearly from the background, 
representing a significant improvement compared with 
conventional MALDI MS methods. According to the MS 
intensity, the concentrations of insulin in these serum 
samples were calculated as shown in Table 2. Compared 
to the insulin level obtained by clinically standard chemi-
luminescence immunoassays (CIA), the immune-MS 
results did not show significant difference, with a p value 
>0.05 (p  =  0.3383, Table  2; Fig.  8). Meanwhile, strong 
correlation of the results tested by CIA with immune-
MALDI MS was also observed (correlation coefficient 
>90%).
In addition, we measured the lysate fluid of rat pan-
creas cell using this developed target plate. The amino 
acid sequences of rat insulin ([M  +  H]+=5805  Da) 
and human insulin ([M + H]+=5809 Da) although dif-
fer by several amino acids, the rat insulin could still 
be recognized by the anti-insulin we applied. The MS 
spectrum (Fig. 9) revealed that the rat insulin in lysate 
fluid also could be directly detected, with a concentra-
tion calculated of around 14 nM. These results further 
exhibited the feasibility of this method for bio-fluids 
analysis.
Conclusion
Here, we proposed a strategy to construct antibody-
functionalized MALDI target plate for fast and high-
throughput MS analysis of insulin. The nanostructure 
on the surface of target plate improved the efficiency of 
antibody coupling and insulin detection. Biological fluids, 
such as serum or cell lysate, could be sensitively analyzed 
using this functional target plate without any pre-purifi-
cation, which is impossible for the conventional MALDI 
MS methods. Furthermore, our method is also useful for 
Fig. 7 MALDI MS spectra of human serum samples. a MS Spectrum 
achieved on conventional target plate. b MS Spectrum achieved on 
anti-insulin antibody decorated GNP-ITO. 3 Replicates for each data 
were tested at the same conditions
Table 2 Insulin levels in 6 human serums tested by chemiluminescence immunoassays (CIA) and the developed immune-
MS method
5 Duplicates of each sample were tested by MALDI MS based on antibody-modified target plate and CIA
a CIA chemiluminescence ImmunoAssays
b MS MALDI MS based on antibody-modified target plate
Serums of patients (accepting insulin therapy)
#1 #2 #3 #4 #5 #6
CIA (nM)a 1.0 3.6 3.2 2.1 3.5 2.3
MS (nM)b 1.3 3.8 3.3 2.2 3.8 2.4
Fig. 8 Comparison of serum insulin levels tested by chemilumines-
cence immunoassays (CIA) and the MALDI MS based on antibody-
modified GNP-ITO (MS). Differences with p values <0.05 were 
considered statistically significant. Data represent MEAN ± SEM
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the immobilization of other antibodies and analysis of 
other types of biomolecules, thus offering a widely-used 
toolbox for the fields of bio-sample exploration.
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